stoxline Quote Chart Rank Option Currency Glossary
Alkermes plc (ALKS)
29.57  0.66 (2.28%)    02-23 16:00
Open: 29.19
High: 29.6
Volume: 1,790,687
Pre. Close: 28.91
Low: 29
Market Cap: 4,938(M)
Technical analysis
2024-02-23 4:34:53 PM
Short term     
Mid term     
Targets 6-month :  38.4 1-year :  44.85
Resists First :  32.88 Second :  38.4
Pivot price 28.5
Supports First :  28.73 Second :  26.18
MAs MA(5) :  30.04 MA(20) :  28.24
MA(100) :  26.83 MA(250) :  28.31
MACD MACD :  0.6 Signal :  0.4
%K %D K(14,3) :  45.3 D(3) :  53.5
RSI RSI(14): 55
52-week High :  33.7 Low :  22.01
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALKS ] has closed below upper band by 36.0%. Bollinger Bands are 133.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 5 days. This is a sign that the current trend might continue.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 29.67 - 29.87 29.87 - 30.04
Low: 28.51 - 28.76 28.76 - 28.99
Close: 29.18 - 29.58 29.58 - 29.94
Company Description

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Headline News

Fri, 23 Feb 2024
Technical Analysis of Alkermes — TradingView News - TradingView

Fri, 23 Feb 2024
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term - Zacks Investment Research

Fri, 23 Feb 2024
Why Alkermes (ALKS) is a Top Momentum Stock for the Long-Term - Yahoo Finance

Fri, 23 Feb 2024
Fuller & Thaler Asset Management Inc. Buys 33089 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat

Fri, 23 Feb 2024
Cantor Fitzgerald Analysts Raise Earnings Estimates for Alkermes plc (NASDAQ:ALKS) - AmericanBankingNEWS

Thu, 22 Feb 2024
Algert Global LLC Increases Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 167 (M)
Shares Float 164 (M)
Held by Insiders 1.2 (%)
Held by Institutions 109 (%)
Shares Short 11,660 (K)
Shares Short P.Month 14,020 (K)
Stock Financials
EPS 3.05
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 7.19
Profit Margin 21.3 %
Operating Margin 14.4 %
Return on Assets (ttm) 12.6 %
Return on Equity (ttm) 46.2 %
Qtrly Rev. Growth 23.8 %
Gross Profit (p.s.) 0
Sales Per Share 9.94
EBITDA (p.s.) 2.93
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 9.66
PEG Ratio 0.4
Price to Book value 4.1
Price to Sales 2.97
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android